Cabozantinib Improves PFS in Patients with Previously Treated, Progressive Advanced Extrapancreatic or Pancreatic Neuroendocrine Tumours By Ogkologos - October 25, 2024 901 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the CABINET study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Announces 2026 Society Award Recipients Honouring Excellence in Cancer Research, Care and Leadership Adjuvant Olaparib Continues to Improve Multiple Outcomes in Patients with Germline BRCA1/2-associated High-Risk HER2-negative EBC EMA Recommends Refusing the Marketing Authorisation for Copper (64Cu) Oxodotreotide MOST POPULAR Treating the Whole Person: How Cancer Centers Are Addressing Social Needs July 18, 2024 Boy Battling Cancer Becomes Honorary Police Officer, Sworn In To 45... January 15, 2022 Research with integrity – why colour blindness is a research integrity... February 28, 2023 Opinion: ‘Medical research charities are falling through the cracks of COVID-19... June 16, 2020 Load more HOT NEWS EMA Recommends Granting a Conditional Marketing Authorisation for Tovorafenib Breathing for Stress Reduction Lorlatinib Continues to Show Long-Term Benefit in Newly-Diagnosed Patients with Advanced... Nivolumab vs Sorafenib in First-Line Treatment of Advanced Hepatocellular Carcinoma
